Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Natrunix in Healthy Subjects
NCT05099510Phase 1Completed
- Sponsor
- XBiotech Inc.
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial comparing Natrunix with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 28 days. Started Jan 2022; status: completed.
02
Drugs
XB2001
Beyond the preview
Go deeper on NCT05099510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099510.